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A Thousand Tiny Pieces:
The Federal Circuit’s Fractured Myriad Ruling, Lessons to
be Learned, and the Way Forward
Jonathan Stroud*
I. Introduction
On July 29, 2011, the Court of Appeals for the Federal Circuit handed down the long-awaited
decision in Association for Molecular Pathology v. U.S. Patent and Trademark Office (AMP
v. USPTO or Myriad I)1 upholding the patentability of claims on isolated human genes2 in a
* Summer Associate, Finnegan, Henderson, Farabow, Garrett, & Dunner LLP, 2012 (expected); Patent Examiner, United
States Patent and Trademark Office, 2007–2012; J.D., American University Washington College of Law, 2013 (expected);
M.A., Print Journalism, University of Southern California, 2006; B.S.E., Biomedical Engineering, Tulane University, 2004.
At American University Washington College of Law, Mr. Stroud is a member of the Moot Court Honor Society, the Senior
Symposium Editor of the Administrative Law Review, and the Senior Symposium Chair for the Intellectual Property Brief.
1. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad I), 653 F.3d 1329, 99 U.S.P.Q.2d (BNA)
1398 (Fed. Cir. 2011), cert. granted, judgment vacated, and remanded sub nom. Ass’n for Molecular Pathology v. Myriad
Genetics, Inc. (Myriad II), No. 11-725, 2012 WL 986819 (U.S. Mar. 26, 2012) (remanding to the Federal Circuit for
further consideration in light of Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012)).
2. Compare James J. Mullen, III & Mary Prendergast, Federal Circuit Decision in Myriad Genetics Confirms that
Isolated Human DNA Molecules Are Patentable, Morrison Foerster (Aug. 1, 2011), http://www.mofo.com/files/
Uploads/Images/110801-DNA-Molecules-Patentable.pdf (highlighting the case as a win for diagnostic manufacturers
interested in isolated human genome testing), with Recent Case, Federal Circuit Invalidates Diagnostic Method
Claims as Drawn to “Abstract Mental Processes.”—Association for Molecular Pathology v. U.S. Patent & Trademark
Office, 653 F.3d 1329 (Fed. Cir. 2011), 125 Harv. L. Rev. 658, 658 (2011) (arguing the case erroneously invalidated
all diagnostic “method patents” under an unadvisable “abstract mental processes” standard), and Courtenay
Brinckerhoff, Federal Circuit Issues Mixed Decision on Myriad Claims, PharmaPatents (July 30, 2011), http://www.
pharmapatentsblog.com/federal-circuit-decisions/federal-circuit-decides-myriad-oks-isolated-dna-claims/ (calling the
Federal Circuit’s Myriad I ruling a “mixed decision” and saying that “there is much to be analyzed before the full impact
of this decision—and the contours of the holdings—will be understood”). See also Seth R. Ogden, Note, The Federal
Circuit’s Decision in Myriad: Isolated DNA Molecules Are Patentable Subject Matter, 61 Am. U. L. Rev. 443 (2011)
and Lisa Larrimore Ouellette, What are the Sources of Patent Inflation, 121 Yale L.J. Online 347, 354 n.40 (2011)
(citing Jonathan Stroud, A Myriad of Reasons: The Federal Circuit Soundly Rejects the Government’s “Magic
Microscope” Test and Upholds Patentability for Isolated Human Gene Patents, Intell. Prop. Brief (Aug. 24, 2011,
4:30 PM), http://www.ipbrief.net/2011/08/24/gues-post-a-myriad-of-reasons-the-federal-circuit-soundly-rejects-thegovernment’s-“magic-microscope”-test-and-upholds-patentability-for-isolated-human-gene-patents)(finding the Federal
Circuit’s ruling in Myriad I soundly upheld gene isolation patents)).
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2–1 decision that has provoked a petition to rehear the case en banc,3 which was denied.4
Subsequently, a Supreme Court petition for certiorari was filed,5 which the high court
recently granted, vacated, and remanded (GVRed) in Association for Molecular Pathology
v. Myriad Genetics (Myriad II)6 in light of their recent decision in Mayo Collaborative
Services v. Prometheus Laboratories, Inc. (Prometheus).7
After the Federal Circuit’s initial decision, the genomic testing startup companies
breathed a collective (if temporary) sigh of relief. That is, until the Supreme Court issued
its recent GVR, thus recreating the original uncertainty surrounding gene patents. The
case is the latest chapter in the AMP v. USPTO saga, which has thrown the biotech world
into turmoil over contentious genetic testing and threatened the future of personalized
medicine in America. The Federal Circuit was right to rule definitively, and it is unfortunate
that the dissenting judge divided the opinion and created uncertainty. The Supreme Court
compounded that uncertainty when they chose to GVR the case and again create a swirl of
confusion where clarity is sorely needed.
In the wake of the Supreme Court’s recent unanimous invalidation of a diagnostic
testing patent in Prometheus as unpatentable subject matter,8 however, commentators have
suggested that the Federal Circuit may reverse the panel decision in light of the Supreme
Court’s unanimous precedent.9 Prometheus indicates that obvious subject matter, coupled
with what the Court believes are laws of nature, is not patentable under § 101. Thus, the
3. Petition for Rehearing En Banc, Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, No.
2010-1406 (Fed. Cir. Aug. 31, 2011).
4. Denial of Petition for Rehearing En Banc, Ass’n for Molecular Pathology v. U.S. Patent and Trademark
Office, No. 2010-1406 (Fed. Cir. Sept. 13, 2011).
5. See Kevin E. Noonan, AMP v. USPTO: Oral Argument at the Federal Circuit, Patent Docs (Apr. 7, 2011,
12:00 PM), http://www.patentdocs.org/2011/04/amp-v-uspto-oral-argument-at-the-federal-circuit.html (“[The
Myriad I case] is likely to be subject to en banc review, a petition for certiorari to the Supreme Court, or both.
The case is far from over.”).
6. See Myriad II, 2012 WL 986819: “The petition for a writ of certiorari is granted. The judgment is vacated,
and the case is remanded to the United States Court of Appeals for the Federal Circuit for further consideration
in light of Mayo Collaborative Services v. Prometheus Laboratories, Inc., 556 U.S. ___ (2012).”
7. Mayo Collaborative Servs. v. Prometheus Labs., Inc., No. 10–1150 (Mar. 20, 2012) (slip op.), available at
http://www.supremecourt.gov/opinions/11pdf/10-1150.pdf.
8. Id. at *8 (asking “do the patent claims add enough to their statements of the correlations to allow the
processes they describe to qualify as patent-eligible processes that apply natural laws?” and stating “We
believe that answer is no.” (emphasis in original)).
9. Dennis Crouch, Mayo v. Prometheus: Natural Process + Known Elements = Normally No Patent,
Patently-O.com (May 20, 2012), http://www.patentlyo.com/patent/2012/03/mayo-v-prometheus-naturalprocess-known-elements-normally-no-patent.html:
Following Mayo, the court could logically find that the information in the DNA represents a law of nature,
that the DNA itself is a natural phenomenon, that the isolation of the DNA simply employs an isolation
process already well known and expected at the time of the invention, and ultimately that the isolated DNA is
unpatentable because it effectively claims a law of nature or natural phenomenon.
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possibly obvious isolation of human genes could be held invalid, as isolation techniques
have existed for some time.
Part II of this Article will give a brief synopsis of the procedural and historical background
of the case and will discuss the importance of the patent claims to the genetic diagnostics
industry and personalized medicine in general. Part III will analyze the Federal Circuit’s
divided opinion; Part IV will discuss Prometheus. Part V will attempt to draw inferences
about the possibilities surrounding Myriad II. Part VI will conclude on a hopeful note.
II. Background
The Patent and Trademark Clause of the U.S. Constitution grants the federal government
the ability to grant patent rights,10 and those laws have been codified for nearly as long
as there has been a United States of America.11 The statutory subject matter requirement
is set forth in 35 U.S.C. § 101, and reads “Whoever invents or discovers any new
and useful process, machine, manufacture, or composition of matter, or any new and
useful improvement thereof, may obtain a patent therefor, subject to the conditions and
requirements of this title.”12 The Courts have usually interpreted the clause broadly, subject
to a few judicially created exemptions.13
A. Procedural Background
Since the Supreme Court ruled in 1980 in Diamond v. Chakrabarty that bioengineered
living organisms are patentable subject matter,14 the USPTO has generally held that isolated
human genes—segments of human genes that have been excised, with non-important parts
spliced out, and then isolated in the laboratory—are patentable,15 to the tune of thousands
of issued patents over the years.16 However, the lower district court in AMP v. USPTO
invalidated patent claims to two controversial isolated genes, the BRCA 1 and 2 genes,
which have been linked to a higher risk of female patients developing breast cancer.
10. “To promote the Progress of Science and useful Arts, by securing for limited Times to Authors and
Inventors the exclusive Right to their respective Writings and Discoveries.” U.S. Const. art. I, § 8, cl. 8.
11. See United States Patent Act, 35 U.S.C. §§ 100–105 (2006) (granting statutory authority to issue 20-year
patents).
12. Id. § 101.
13. See Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office (Myriad I), 653 F.3d 1329, 1348
(Fed. Cir. 2011) (discussing the “broad, [but] not unlimited” nature of § 101).
14. 447 U.S. 303, 310 (1980) (stating that the ability of man resulted in bacteria with “markedly different
characteristics” and the “potential for significant utility”).
15. See, e.g., 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001) (formally stating said longstanding policy).
16. See Myriad I, 653 F.3d at 1355 (“It is estimated that the PTO has issued 2,645 patents claiming ‘isolated
DNA’ over the past twenty-nine years, and that by 2005, had granted 40,000 DNA-related patents covering,
in non-native form, twenty percent of the genes in the human genome.”(internal citations omitted)); id. at
1367 (Moore, J., concurring) (“[T]here are now thousands of patents with claims to isolated DNA, and some
unknown (but certainly large) number of patents to purified natural products or fragments thereof.”).
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The case was a surprise to many17 and threw the market for many start-up biotech companies
into disarray, as a judicial cloud settled over their isolated gene patents.18 Complicating matters
further, the Justice Department and the U.S. Solicitor General took an interest in the case, and
although the Solicitor General of the USPTO generally argues cases in front of the Federal
Circuit on behalf of the government, instead the Justice Department unprecedentedly stepped
in with a largely contrary position from the one the USPTO had long held.19
B. Personalized Medicine, Diagnostic Companies, and You
Personalized Medicine is the use of an individual’s characteristics, in particular, their
genetic information, to target medicines to the individual rather than administer traditional
drugs in the same form and dose to all patients, in a one-size-fits-all model.20 It has been
heralded by the heads of the FDA and the NIH as the future of medicine,21 and involves
packaging genetic diagnostic testing and targeted medicines together, such as the recently
FDA-approved cancer treatments crizotinib, and its genetic associated test.22
17. See, e.g., Robert Carlson, Surprise District Court Ruling Invalidates Myriad Genetics’ BRCA Patents, But Appeal
Is Pending, Biotech. Healthcare (Summer 2010), at 8–9, available at http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2899793/.
18. Id. (saying that members of the bar were “surprised” and “dismayed” and that it was “contrary to . . .
Federal Circuit precedent”).
19. See Jonathan Stroud, Myriad Madness—How the Department of Justice is Working Counter to U.S.
Interests, Intell. Prop. Brief (Feb. 22, 2011, 7:00 AM), http://www.ipbrief.net/2011/02/22/myriad-madness%E2%80%93-how-the-department-of-justice-is-working-counter-to-u-s-interests/ (“This highly unusual
request by the Justice Department—preempting the Department of Commerce’s usual role in appellate-level
arguments for all patent cases—only highlights the deep divisions between the two agency’s positions.“). The
Federal Circuit referred to the infighting obliquely:
Although the PTO did not “sign” the brief and we are left to guess about the status of any possible continuing
inter-agency disagreements about the issue, the Department of Justice speaks for the Executive Branch, and the
PTO is part of the Executive Branch, so it is fair to assume that the Executive Branch has modified its position
from the one taken by the PTO in its 2001 guidelines and, informally, before that.
Myriad I, 653 F.3d at 1380–81 (majority opinion).
20. See generally Frances S. Collins, The Language of Life: DNA and the Revolution in Personalized Medicine
(2010) (discussing the future of genetics and the biotech industry).
21. See Margaret A. Hamburg & Francis S. Collins, The Path to Personalized Medicine, 363 New Eng. J. Med. 301,
301–04 (2010) (calling for greater collaboration between the Food and Drug Administrative (FDA) and the National
Institute of Health (NIH)) Cf. Jonathan Stroud, Comment, The Illusion of Interchangability: The Benefits and Dangers
of Guidance-Plus Rulemaking in the FDA’s Biosimilar Approval Process, 63 Admin. L. Rev. 599, 606, 637 (2011)
(discussing the recent statutory solution of an abbreviated pathway for biosimilars, and suggesting the pathway will
save biologics makers millions of dollars in the approval process via “price competition” and “reduced approval
costs”).
22. Molly Peterson, Pfizer Wins U.S. Approval for Lung Cancer Drug Seen as Filling Lipitor Gap, Bloomberg News
(Aug. 27, 2011), http://www.bloomberg.com/news/2011-08-26/pfizer-wins-u-s-approval-for-tumor-fighting-medicineto-treat-lung-cancer.html (reporting that Pfizer won approval of the drug, which is targeted to a specific form of lung
cancer caused by a gene defect, along with the related genetic test approved by Abbott Labs); see also Abbott Says
FDA Clears Leukemia Genetic Test, Yahoo! News (Aug. 22, 2011), http://news.yahoo.com/abbott-says-fda-clearsleukemia-genetic-test-154708318.html (citing approval of a similar genetic test for leukemia).
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In 2004, the Food and Drug Administration (FDA) approved a similar drug called erlotinib
as a second-line defense for a subset of lung cancer patients.23 In various clinical tests, the
drug has produced uneven—but dramatic—results. Some patients had 30% shrinkage of their
tumors; others had an amazing 99% shrinkage, nearly curing them entirely;24 and some had
almost no shrinkage at all.25 This had some calling it a miracle drug,26 while others questioned
the wisdom of approving a costly drug treatment that conveyed to many the false hope of
a dramatic cure.27 Nonetheless, the U.S. manufacturer Genentech has encouraged clinical
research, and recent results have shown that clinicians can identify smaller and smaller
subsets of lung cancer patients who will benefit through genetic testing.28
Recently, the National Comprehensive Cancer Network and the American Society
of Clinical Oncology (ASCO) recommended lung cancer patients be screened for a specific
genetic mutation—EGFR—to identify patients most likely to benefit from the drug.29 By
combining the expensive drug with the genetic test, researchers believe patient outcomes
can be improved,30 while others who might respond poorly to the medication can be
23. Tarceva® Erlotinib Tablets, Genentech, http://www.gene.com/gene/products/information/oncology/
tarceva/ (last visited Mar. 19, 2012) (“Tarceva® (erlotinib) is a small molecule human epidermal growth factor
type 1/epidermal growth factor receptor (HER1/EGFR) inhibitor which demonstrated, in a Phase III clinical
trial, an increased survival in advanced non-small cell lung cancer (NSCLC) patients.”).
24. Howard Hughes Med. Inst., Genetic Accomplice Helps Some Lung Tumors Evade Treatment (Mar. 23,
2011), available at http://www.hhmi.org/news/pdf/sawyers20110323.pdf (“Within weeks, [erlotinib] can shrink
tumors with a particular mutation to near vanishing. But the drug does not work equally well in all patients. For
others with the same mutation, the results can be disappointing. Tumors may only shrink by 30 percent.”).
25. Heidi Ledford, Mutations Block Lung-Cancer Treatment, Nature (Mar. 23, 2011), http://www.nature.com/
news/2011/110323/full/news.2011.178.html (“These drugs help most patients: about three quarters of those
with EGFR-activating mutations respond well to gefitinib [a related EGFR-inhibitor], for example. But the rest
respond poorly, if at all, and no one knows why.”).
26. Id. (“For some patients with lung cancer, the drug erlotinib is a near miracle.”); see also Some
of Our Survivors Call It the “Miracle Drug,” Bonnie J. Addario Lung Cancer Found., http://www.
lungcancerfoundation.org/2009/03/19/some-of-our-survivers-call-it-the-%E2%80%9Cmiracledrug%E2%80%9D/ (last visited Mar. 19, 2012).
27. Goran Mijuk & Sten Stovall, Roche’s UK Drug Appeal Failure Underscores Problems, Dow Jones
Deutschland (June 29, 2011), http://www.dowjones.de/site/2011/06/roches-uk-drug-appeal-failure-underscoresproblems.html (discussing the manufacturer’s “increasing problems with government bodies that view its
medicines as too expensive” and pegging the cost of treatment at “between $30,000 to $60,000 per year”).
28. Trever G. Bivona et al., FAS and NF-κB Signalling Modulate Dependence of Lung Cancers on Mutant
EGFR, 471 Nature 523, 523–26 (2011) (finding that with Tarceva “the magnitude of tumour regression is
variable and transient” and that “this . . . could result from genetic modifiers that regulate the degree to which
tumour cells are dependent on mutant EGFR”).
29. Patrice Wendling, Mutation Testing Guided Erlotinib Prescribing in Lung Cancer, Internal Med. News
Digital Network (July 11, 2011), http://www.internalmedicinenews.com/views/observation-unit/blog/
mutation-testing-guided-erlotinib-prescribing-in-lung-cancer/31b54c31e5.html.
30. Fred Hirsch, The Role of Genetic Testing in the Prediction of Response to EGFR Inhibitors in NSCLC, 28
Oncogene S1, S1–S3 (2009) (releasing clinical findings that “pretreatment detection of such markers could
facilitate a more personalized and specific approach to therapy, whereby the most appropriate and efficacious
treatment is selected for a specific subset of patients”).
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screened out.31 It would also justify the high cost to the small subset of users who would
benefit. Yet it has taken more than five years to make even this modest suggestion that
targeted testing can improve outcomes. So this and similar drugs’ future effectiveness seems
to be pegged to the successful implementation of a very specific genetic test.32
Indeed, the NIH recently announced it would, and now has, published a Genetic Testing
Registry by early 2012, highlighting commercial genetic testing’s growing importance.33
However, the registry is voluntary,34 and there is still a vast need for patent protection,
especially in light of the FDA’s confused treatment of genetic tests.
Over the past fifteen years, the FDA had begun to assert jurisdiction over laboratory
diagnostic tests (LDTs) and end their long-practiced enforcement discretion.35 In July of 2010, the FDA
held a public meeting announcing its intent to regulate LDTs based on the risks that they posed, and
stated that guidance would follow.36 Then on July 11, 2011 the FDA issued draft guidance on what they
termed “in vitro companion diagnostic devices” (IVCDDs).37
In it, the FDA would require that the innovator seek FDA approval for new medical
products (drugs and biologics) under either § 505 of the Federal Food, Drug, and
Cosmetic Act (FDCA) (drugs)38 or § 351 of the Public Health Service Act (PHSA)
31. See id. (“EGFR mutation testing is ready for routine clinical use and [more targeted] testing will soon be
ready.”); cf. Peggy Peck, Tarceva Improves Survival in Subset of Patients with Refractory Non-Small Cell Lung
Cancer, MedPage Today (July 13, 2005), http://www.medpagetoday.com/Pulmonology/LungCancer/1353
(“While supporters of Tarceva . . . hailed [positive clinical trial results] as a major advance in ‘personalized
medicine,’ the absolute numbers were less than overwhelming.”).
32. Accord Food & Drug Admin., Draft Guidance for Industry and Food and Drug Administration Staff:
In Vitro Companion Diagnostic Devices 5 n.2 (2011) [hereinafter Draft Guidance], available at http://www.
fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf
(using Herceptin and the associated test as another example of a treatment combination which is only useful
for metastatic breast cancer and gastric cancer if the patient has the HER-2 genetic marker, which the test
reveals).
33. Genetic Testing Registry, Nat’l Ctr. for Biotechnology Info., http://www.ncbi.nlm.nih.gov/gtr/ (last visited
Jan. 20, 2012) (“Once operational, GTR will provide access to information about genetic tests for inherited and
somatic genetic variations, including newer types of tests such as arrays and multiplex panels.”).
34. Id. (“GTR information about tests primarily will be based on voluntary data submissions by test developers
and manufacturers.”).
35. See, e.g., In Vitro Diagnostic Products For Human Use, 21 C.F.R. pt. 809 (2012); Sec’y’s Advisory Comm.
on Genetics, Health, and Soc’y (SACGHS), U.S. System of Oversight of Genetic Testing: A Response to the
Charge of the Secretary of Health and Human Services (2008), http://oba.od.nih.gov/oba/SACGHS/reports/
SACGHS_oversight_report.pdf (recommending greater FDA oversight of laboratory diagnostic tests (LDTs)
consistent with in vitro diagnostics (IVDs)).
36. FDA/CDRH Public Meeting, Oversight of Laboratory Developed Tests (LDTs) (July 19–20, 2010),
available at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm212830.htm.
37. Draft Guidance, supra note 32, at 3, 7.
38. Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, ch. 675, § 505, 52 Stat. 1040, 1055 (codified as
amended in scattered sections of 21 U.S.C.).
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(biologics),39 while the innovator must seek contemporaneous approval for the IVCDD
under § 510(k) of the Medical Device Amendments40 to the FDCA.41 Effectively, it
would assert jurisdiction over any new laboratory tests that it are “essential for the safe
and effective use of a corresponding therapeutic product.”42 It also seems to require FDA
approval for such tests as full IVCDDs, subject to exceptions for products that threat serious
or life-threatening conditions or already-approved products.43
This would ostensibly prevent drug companies from seeking approval for drugs like
crizotinib or erlotinib without also approving and commercializing the much-needed
test and relying instead on variable LDTs nationwide. It also serves to expand the FDA’s
authority over such devices and would affect drug approvals: For instance, an expensive
medicine with a small targeted population could possibly fail approval as not being
“effective” enough to be generally prescribed, unless it was also coupled with the test,
which the FDA would, under this guidance, require. Lastly, it begins the slow transition to
a regulatory framework that considers IVDs an essential part of medical treatment. There
is also a companion legislative push to regulate by statute the devices under a separate
pathway at the FDA.44 This would lower the cost of premarket approval and allow smaller
companies to get their commercialized diagnostic tests to market.
However, until the Congress or the FDA acts to streamline the approval process, currently
the only readily available path to commercialization for small companies is the patent
process. Companies seeking to commercialize research and development—particularly
university spinouts and start-up companies—need a fast and effective way to protect
their research and commercialize their genetic tests, and isolated gene patents have been
the primary vehicle to do so, particularly for companies like Myriad that do not have the
39. Public Health Service Act, Pub. L. No. 78-410, ch. 373, 58 Stat. 682 (codified as amended at 42
U.S.C. §§ 262–300jj, 351 (2006 & Supp. II 2006)).
40. Pub. L. No. 94-295, 90 Stat. 539 (codified as amended in scattered sections of 21 U.S.C.).
41. Draft Guidance, supra note 32, at 7.
42. See id. at 6.
43. See id. at 8–9.
44. Advocates of FDA enforcement authority over LDTs and industry representatives seeking a clear pathway
to approval for more targeted medicines in the development pipeline have begun to lobby Congress to expand
the regulatory authority of the FDA to include all commercially available laboratory tests of any targeted
therapeutic significance. See Scott Gottlieb, Will Regulation Thwart the Personalization of Medicine?, Health
Pol’y Outlook 3 (Am. Enter. Inst. for Pub. Policy Research, Wash., D.C.), Oct. 2010, at 7, http://www.aei.
org/files/2010/10/22/2010-10-No-3-g.pdf (advocating for a legislative solution to the regulatory problem). The
easiest vehicle to amend the law would be the reauthorization bill of the Prescription Drug User Fee Act, a
widely popular bill that is up for reauthorization in 2012. See id. at 7 (“The way to change LDT regulation may
be the reauthorization of the Medical Device User Fee and Modernization Act next year, rather than the FDA’s
internal policy process. Legislation is likely to get coupled to the act that would give the FDA new authority
over LDTs.”). The draft legislation getting the most attention—that is under development by Senator Orrin
Hatch’s office—is the Better Evaluation and Treatment Through Essential Regulatory Reform for Patient Care
(BETTER Patient Care) Act of 2011. Senate Legislative Council (2011) (draft legislation) (on file with author).
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resources of a Pfizer or an Abbott Labs to undergo the expensive and time-consuming FDA
approval process (as it now stands). Thus, the importance of the USPTO v. AMP decision
for that industry cannot be overstated: In this context, it is an all-or-nothing affair. These
companies need these patents to survive and continue to innovate, unless and until Congress
or the FDA reform to the point where these products can be approved cheaply.
C. Myriad Possible Interpretations
The instant cases, Myriad I & II, pit concerned doctors and women’s health groups against
the company that isolated the gene and developed and patented the genetic test.45 They rest
largely on two very distinct ways of seeing the science behind isolating the human genome.
The first could be called the “informational” view, and is the argument that won the day in the
lower court—that the human genome represents information and sequences that occur naturally,
and thus cannot be patented. The second can be called the “chemical” or “mechanical” view,
and it posits that the isolated molecules—which have been chemically cleaved, separated, and
do not occur in this chemically differing state in nature—are “markedly different” under the
Chakrabarty test and have distinct utility (as primers and test pieces).46
III. The Federal Circuit’s Split Decision
The Attorney General’s office argued for the former in this case, positing a “magic
microscope” test in oral argument, where if one were to magnify the human genome, one
could see the sequence as claimed in the patent.47
In the majority opinion, Judge Lourie flatly rejected that test,48 and adopted the
“chemical” view outlined above.49 The majority found that the chemical cleaving of the
bonds that connect all human genomes produced a markedly different chemical structure
than the one found in nature, and thus the resulting invention was patentable.50 Arguing
against the dissent, the majority clearly found the informational view lacking, making a
clear distinction between claims over structure and claims over function.51 Further, the
45. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office (Myriad I), 653 F.3d 1329, 1329 (Fed.
Cir. 2011).
46. Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980).
47. See Myriad I, 653 F.3d at 1350.
48. Id. at 1368–70 (stating the magic microscope test “has curb appeal” in its “child-like simplicity” but that
ultimately it is not a “limited position” as the government asserted, and the government is “wrong”).
49. Id. at 1353 (“Visualization does not cleave and isolate the particular DNA; that is the act of human
invention.”).
50. Id. (“The government’s microscope could focus in on a claimed portion of any complex molecule, rendering
that claimed portion patent ineligible, even though that portion ever exists as a separate molecule in the body or
anywhere else in nature, and may have an entirely different utility. That would discourage innovation.”).
51. Id. (“We recognize that biologists may think of molecules in terms of their uses, but genes are in fact
materials having a chemical nature and , as such, are best described in patents by their structures rather than
their functions.”).
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majority stressed the “utility” of the invention, and the “markedly different” or “distinctive”
characteristics.52
In a remarkably well-written concurring opinion, Judge Moore said that, at least with
regards to a certain set of broad claims, it was a much closer question, but that the economic
reliance interests and the long-settled expectations of the biotechnology industry tipped the
scales in favor of allowing patentability on isolated genes (as the USPTO and the Federal
Circuit always have).53
This is a pragmatic argument that takes into account the large number of property rights
that the Court would be strip from inventors and former applicants, many of whom have
been relying on their isolated gene patents for decades. Yet the bulk of both opinions rest on
the hard science—the chemistry of chemical bonds—complete with charts and diagrams,
and resists devolving into sentimental policy judgments. At the end of the day, § 101 is not
the avenue to invalidate these patents; Congress is.
In one of the more memorable lines of the case, the majority seemed to rebuke the lower
court’s lengthy opinion, urging deference to Congress and endorsing judicial minimalism:
“[C]ourts decide cases, they do not draft legal treatises.”54
IV. Prometheus-Bound
Then beneath the earth those hidden blessings for man, bronze, iron,
silver and gold—who can claim to have discovered before me? No one,
I am sure, who wants to speak to the purpose. In one short sentence
understand it all: every art of mankind comes from Prometheus.
—Aeschylus (generally attributed)55
On March 20, 2012, the Supreme Court complicated matters when it unanimously held
in Prometheus that a diagnostic method patent was invalid under § 101 because it “set forth
52. Id. at 1351 (“Applying this test to the isolated DNA in this case, we conclude that the challenged claims
are drawn to patentable subject matter because the claims cover molecules that are markedly different—have a
distinctive chemical identity and nature—from molecules that exist in nature.”).
53. Id. at 1367–73 (Moore, J., concurring-in-part). I argued this back in November 2010:
Because it will fuel scientific progress, give a reasonable financial incentive to companies interested in genomics, and
lead to further research in this rapidly expanding field, not to mention the fact that it is consistent with prevailing Federal
Circuit precedent, the court should overturn this dangerous ruling. The government should not support the ruling, which
in effect would invalidate over 2,000 genomic patents. Jonathan Stroud, The Government is Wrong: The Case for
Human Gene Patents and the Genomics Revolution, Intell. Prop. Brief (Nov. 2, 2010, 10:30 AM) http://www.ipbrief.
net/2010/11/02/the-government-is-wrong-the-case-for-human-gene-patents-and-the-genomics-revolution/.
54. Myriad I, 653 F.3d at 1354 (majority opinion).
55. Aeschylus, Prometheus Bound (Greek Tragedy in New Translations) ll. 498–505 (James Scully & C. John
Herington trans., University Oxford Press 1975) (c. 415 B.C.E.).
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laws of nature”—relationships between blood-borne metabolites and the appropriate dosage
of a dangerous drug—rather than a patentable diagnostic process.56 It held that diagnostic
patents that apply so-called natural laws using known processes are invalid, and it held that
the underlying mathematical relationship between metabolite levels of the blood and the
drug thiopurine was an immutable law of nature.57
Thus, the Supreme Court endorsed a “law-of-nature-plus-obviousness” methodology for
analyzing unpatentable subject matter under § 101, whereby any mathematical equation or
natural relationship that is applied using an already-known methodology is invalid under § 101.58
The Court noted that many argued in the case that “a principle of law denying patent
coverage here will interfere significantly with the ability of medical researchers to make
valuable discoveries, particularly in the area of diagnostic research,”59 but found equally
compelling the counter-argument brought by, among others, the Association for Molecular
Pathology, the petitioner in Myriad I & II.60 They argued that if patent protection is allowed
over the body’s natural response to drugs, then “the result will be a vast thicket of exclusive
rights over the use of critical scientific data that must remain widely available if physicians
are to provide sound medical care.”61
Justice Breyer was seemingly nervous about ruling in such a way as to protect the
medical diagnostic industry that might have produced unforeseen results in other fields of
technology,62 for instance, in internet patents. Frustratingly, the Court sidestepped the issue,
stating, “we must recognize the role of Congress in crafting more finely tailored rules where
necessary” and “we need not determine here whether, from a policy perspective, increased
protection from discoveries of diagnostic laws of nature is desirable.”63 Indeed, the Court
chose not to address the issue at all, much to the chagrin of the Author and the entire
diagnostic testing community.
Thus, it is an open question whether human genomic sequences might rise to the level of
natural laws isolated via a known means of isolation, or whether the Federal Circuit may
hold that the isolation of specific genes is a non-obvious means of harnessing and testing for
the gene and uphold Myriad II based on the analysis put forth in Prometheus.
56. Mayo Collaborative Servs. v. Prometheus Labs., Inc., No. 10–1150, at *8 (Mar. 20, 2012) (slip op.),
available at http://www.supremecourt.gov/opinions/11pdf/10-1150.pdf.
57. Id.
58. Id.; accord Crouch, supra note 9 (suggesting that the new test invalidates any natural process coupled with
known elements).
59. Prometheus, No. 10–1150, at *23.
60. Id.
61. Id. (quotation and citation omitted).
62. Id. at *24 (“In consequence, we must hesitate before departing from established general legal rules lest a
new protective rule that seems to suit the needs of one field produce unforeseen results in another.”).
63. Id. (citation omitted).
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V. Inferences and Arguments
The Federal Circuit’s majority opinion in Myriad I argued persuasively, adopted the
chemical view, and was the correct position; and Judge Moore’s concurrence eloquently
bolstered the Court’s position. While both the majority and the concurring opinion
weakened the dissent’s reasoning, both make a persuasive case based on sound scientific
and economic principles. The validity and strength of the ruling, however, has been cast
into doubt by the binding precedent of Prometheus. Yet to understand the lingering doubts,
the emotional resonance of the dissent, and the uncertainty cast on the case by the Supreme
Court’s GVR, one must look to the underlying issue in the case.
The unspoken view at the heart of the conflict, one that does not appeal to the scientist
or even to legal reason but rather to baser emotions, is the basic “my body, my property”
view. This view essentially conflates the genetic information that is common to most human
beings—and hence the potential unlocked when its sequence is discovered—with a person’s
own individual DNA. The logic is simple—the DNA is mine. No one else can own it. It
conjures up images of human organ trafficking and reminds us of dystopian science fiction
plotlines about commoditized body parts, and it ostensibly raises issues about personal
privacy and bodily autonomy. Like the magic microscope test or the dissent’s leaf test, it
has “curb appeal” and “a childlike simplicity,”64 but it ultimately oversimplifies and perhaps
misunderstands the issues in the case in a play to emotions.
It would be intellectually disingenuous to say that the true issue is over personal
autonomy. The problem is that Myriad did not seek to buy or sell any individual’s particular
genome, or genetic material, or even to prevent them from analyzing it—they sought to
exclude others from making or using only the test for analyzing it that they innovated.
Beyond the emotional appeal, we must understand the pragmatic effects of such a
limited ruling. Without allowing such patents to stand, the court would doom the nascent
personalized medicine movement that has given us erlotinib and crizotinib, and it would
render targeted care more difficult to innovate and thus provide. Complex companion tests,
IVCDDs, and LDTs, would not be commercially viable at all without such patent protection
and a strong FDA approval pipeline, and companies would be forced to abandon promising
treatments to seek greener pasteurizations, so to speak.
The true underlying issue we must keep in mind is not the existence of the test Myriad
developed—it is the cost. All agree that the test itself is highly beneficial and may save lives; why
else would so many people and groups be interested in the test in the first place? The question is
whether the patent system is the appropriate vehicle for protecting genetic diagnostic testing.
In response, you do not throw the baby out with the bathwater. One may not always like
the cost of prescription medicines, but sick patients are still better off when beneficial drugs
64. See supra note 48 and accompanying text.
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and companion tests exist and are generally available. Patent protection may be too long,65
too exclusive,66 or too over-enforced,67 but allowing the Courts to alter precedent and simply
invalidate the patents entirely in one broad stroke is not the solution.
Nor should the Prometheus decision alter this ruling. The Myriad company invested a
large amount of time and money locating, identifying, and isolating the genes in question,
and then recreating the unique methodology required to isolate these particular genes on
a commercial scale. Thus, even if isolating other genes is a known method of testing for
them, the isolation of each specific gene requires a unique chemical methodology that is not
generally known at the time of patent filing. I believe the Federal Circuit understands the
unique nature of this chemical process, and will uphold their initial ruling after applying the
Prometheus framework by determining that the isolation method patented was, in fact, as
non-obvious as the underlying genes it isolates. At the worst, they should limit the scope of
the independent claims in light of the specific embodiments outlined in the specification.
Ultimately, however, the true solution to this problem, as Justice Breyer suggested, is
through effective legislative and administrative regulation of commercialized diagnostic
genetic tests, and strong patent protection for isolated gene patents targeting specified
genomes. Only then can personalized medicine truly flourish, while still generating jobs,
innovation, and economic growth. Myriad II should be again upheld by the Federal Circuit.
VI. Conclusion
In conclusion, the majority and concurring opinions in Myriad I provide strong positions
from which to defend the longstanding practice of allowing patents on chemically isolated
human genomes, but it remains to be seen whether the Supreme Court’s Prometheus ruling
has significantly altered the analysis to the point where they must reverse their ruling.
Until then, the genomic and diagnostic start-up market will suffer the consequences of that
uncertainty. Hopefully, the Federal Circuit will quickly issue an opinion reaffirming their
previous ruling in light of the Prometheus framework, and thus re-inject certainty into a
market that is one of America’s brighter spots in terms of innovation, job creation, and
economic growth. At the least, they can reinforce thousands of preexisting property rights,
uphold stare decisis, and leave it to Congress to legislate the difficult policy questions.

65. Cf. Gideon Parchomovsky & Michael Mattioli, Partial Patents, 111 Colum. L. Rev. 207, 208–09 (2011)
(introducing the idea of partial patents and semi-patents which offer variable protection over the current onesize-fits-all model, in order to increase use and access to technologies while reducing the cost of innovation).
66. Cf. id. at 208 (arguing partial patents that allow enforcement only against rival commercial entities would
help spur innovation and limit deleterious exclusion).
67. Cf. id.
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